Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | UTHR |
---|---|---|
09:32 ET | 2597 | 274.56 |
09:36 ET | 200 | 274.53 |
09:38 ET | 495 | 274.48 |
09:39 ET | 300 | 272.6001 |
09:41 ET | 464 | 273.86 |
09:45 ET | 200 | 273.77 |
09:48 ET | 200 | 273.77 |
09:50 ET | 1800 | 273.65 |
09:52 ET | 733 | 272.985 |
09:54 ET | 220 | 272.99 |
09:56 ET | 200 | 272.5901 |
09:57 ET | 813 | 273.39 |
09:59 ET | 1405 | 274.01 |
10:01 ET | 200 | 273.92 |
10:03 ET | 100 | 273.92 |
10:06 ET | 100 | 273.8 |
10:08 ET | 100 | 273.945 |
10:10 ET | 1405 | 274.28 |
10:12 ET | 2979 | 274.135 |
10:14 ET | 318 | 274 |
10:15 ET | 594 | 274.505 |
10:17 ET | 400 | 274.77 |
10:19 ET | 388 | 274.3622 |
10:21 ET | 200 | 274.505 |
10:24 ET | 300 | 274.16 |
10:26 ET | 1300 | 274.9325 |
10:28 ET | 1849 | 274.1897 |
10:30 ET | 700 | 274 |
10:32 ET | 302 | 273.77 |
10:33 ET | 700 | 274.035 |
10:35 ET | 300 | 274.285 |
10:37 ET | 200 | 274.37 |
10:39 ET | 400 | 274.72 |
10:42 ET | 400 | 274.66 |
10:44 ET | 1700 | 275.105 |
10:46 ET | 200 | 274.74 |
10:48 ET | 300 | 274.44 |
10:50 ET | 500 | 274.75 |
10:51 ET | 650 | 274.65 |
10:53 ET | 400 | 274.78 |
10:55 ET | 900 | 274.82 |
10:57 ET | 200 | 275.12 |
11:00 ET | 1349 | 275.115 |
11:02 ET | 200 | 275.38 |
11:06 ET | 100 | 275.355 |
11:08 ET | 964 | 275.54 |
11:09 ET | 1700 | 275.45 |
11:11 ET | 1900 | 275.6862 |
11:15 ET | 100 | 275.725 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
United Therapeutics Corp | 12.3B | 13.0x | +8.22% |
Biomarin Pharmaceutical Inc | 14.5B | 71.2x | --- |
Medpace Holdings Inc | 12.1B | 40.1x | +35.10% |
Exact Sciences Corp | 9.9B | -38.1x | --- |
Neurocrine Biosciences Inc | 14.0B | 38.6x | +62.04% |
Qiagen NV | 9.7B | 28.5x | +12.66% |
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.3B |
---|---|
Revenue (TTM) | $2.5B |
Shares Outstanding | 44.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $21.13 |
Book Value | $127.23 |
P/E Ratio | 13.0x |
Price/Sales (TTM) | 4.9 |
Price/Cash Flow (TTM) | 11.1x |
Operating Margin | 50.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.